Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...
In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...
Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...
Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...
In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...
India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...
SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...
Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...
BHUBANESWAR: In a significant medical breakthrough, India's first human gene therapy with a lentiviral vector for severe haemophilia-A has been found to be succ ...
In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback